Midazolam and pentobarbital for refractory status epilepticus

Area of Science:

• Pediatric Neurology
• Emergency Medicine
• Pharmacology

Background:

• Status epilepticus (SE) is a life-threatening neurological emergency common in children.
• Refractory status epilepticus (RSE) requires advanced treatment beyond initial seizure control.
• High-dose pentobarbital is a traditional treatment for pediatric RSE.

Purpose of the Study:

• To compare the efficacy and safety of midazolam versus pentobarbital for pediatric RSE.
• To evaluate midazolam as a novel treatment option for RSE in children.

Main Methods:

• Systematic review of published reports on midazolam and pentobarbital use in pediatric RSE.
• Comparative analysis of treatment outcomes, including seizure termination and adverse events.

Main Results:

• Both midazolam and pentobarbital effectively terminated refractory seizures.
• Pentobarbital use was associated with significant adverse effects, including hypotension and pneumonia.
• Midazolam demonstrated effectiveness with a favorable safety profile and good tolerability.

Conclusions:

• Midazolam is a valuable and well-tolerated option for managing pediatric refractory status epilepticus.
• Midazolam presents a safer alternative to pentobarbital in this critical pediatric condition.